Monoclonal antibody HCV‐AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study
Thomas D. Schiano, Michael Charlton, Zobair Younossi, Eithan Galun, Timothy Pruett, Ran Tur‐Kaspa, Rachel Eren, Shlomo Dagan, Neil Graham, Paulette V. Williams, John Andrews – 24 August 2006 – A randomized, double‐blind, dose‐escalation study evaluated the safety and efficacy of hepatitis C virus (HCV)‐AbXTL68, a neutralizing, high‐affinity, fully human, anti‐E2 monoclonal antibody, in 24 HCV‐positive patients undergoing liver transplantation.